5 Key Takeaways
-
1
The MHRA has authorized Moderna's updated COVID-19 mRNA vaccine, Spikevax®, for adults and children six months and older.
-
2
The updated Spikevax® vaccine targets the SARS-CoV-2 LP.8.1 variant and will be supplied for the 2026 NHS COVID-19 vaccination campaign.
-
3
Moderna's LP.8.1 vaccine is the first commercially available mRNA vaccine manufactured in the UK, enhancing local vaccine resilience.
-
4
The MITC in Harwell, Oxfordshire, supports the UK’s pandemic preparedness through on-shoring vaccine manufacturing and research.
-
5
The MHRA's approval aligns with WHO recommendations for updating COVID-19 vaccines, with similar approvals from the FDA and EMA.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
